Managing asthma: An evidence-based approach to optimizing inhaled corticosteroid treatment

Southern Medical Journal

Volumn 103, Issue 10, 2010, Pages 1038-1044

  Fromer, Leonard ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Asthma; Chronic care model; Inflammation; Inhaled corticosteroids; Patient centered medical home model

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CICLESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUNISOLIDE; FLUTICASONE PROPIONATE; GLUCOCORTICOID; IMMUNOMODULATING AGENT; INFLUENZA VACCINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING BETA 2 AGONIST; METHACHOLINE; METHYLXANTHINE DERIVATIVE; MOMETASONE FUROATE; NEDOCROMIL; SHORT ACTING BETA 2 AGONIST; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; ANTIASTHMATIC AGENT;

ALLERGIC RHINITIS; ASTHMA; CATARACT; CHRONIC DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DRY POWDER; DYSPHONIA; EVIDENCE BASED MEDICINE; FORCED EXPIRATORY VOLUME; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; HOARSENESS; HOME CARE; HOSPITALIZATION; HUMAN; IMMUNOTHERAPY; INFLUENZA; LUNG FUNCTION; METERED DOSE INHALER; MORBIDITY; MORTALITY; OSTEOPOROSIS; PATIENT CARE; PATIENT COMPLIANCE; PHYSICIAN; PRACTICE GUIDELINE; PRICK TEST; PROVOCATION TEST; QUALITY OF LIFE; REVIEW; RISK FACTOR; SKIN TEST; SKIN THINNING; SPIROMETRY; SUBCUTANEOUS ALLERGEN IMMUNOTHERAPY; SUPPRESSION OF HYPOTHALAMIC PITUITARY ADRENAL AXIS FUNCTION; THORAX RADIOGRAPHY; THRUSH; TREATMENT INDICATION; TREATMENT OUTCOME; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ASTHMA; HUMANS; MEDICATION ADHERENCE; PATIENT-CENTERED CARE; PRACTICE GUIDELINES AS TOPIC;

EID: 77958124656     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181ebec5c     Document Type: Review

References (51)

1. GINA - the global initiative for asthma. 2008. Available at: http://ginasthma.org. Accessed May 13, 2009.
2. National Center for Health Statistics. Asthma prevalence, health care use and mortality: United States, 2003-2005. Available at: http://www.dcd.gov/nchs/ products/pubs/pubd/hestats/asthma03-05/asthma03-05.htm 2009.
3. Horak E, Sawyer SM, Roberts M, et al. Impact of disease severity on quality of life in adults with asthma. Wien Klin Wochenschr 2005;117: 462-467.
4. Carlton BG, Lucas DO, Ellis EF, et al. The status of asthma control and asthma prescribing practices in the United States: results of a large prospective asthma control survey of primary care practices. J Asthma 2005;42:529-535.
5. Asthma and Allergy Foundation of America. Cost of asthma. 2006. Available at: http://www.aafa.org/display.cfm?id=6&sub=63.
6. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact [review]. J Allergy Clin Immunol 2001; 107:3-8.
7. QuickStats: health-care visits for asthma, by medical setting and healthinsurance status - United States, 2003 [serial online]. MMWR Morb Mortal Wkly Rep 2006;55:405.
8. National Heart Lung and Blood Institute, National Asthma Education and Prevention Program. Managing Exacerbations of Asthma: Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma [serial online]. Bethesda, National Asthma Education and Prevention Program, National Heart Lung and Blood Institute, 2007, 373-417.
9. Braman SS. The global burden of asthma. Chest 2006;130:4S-12S.
10. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995;152:1107-1136.
11. Adams RJ, Wilson DH, Taylor AW, et al. Coexistent chronic conditions and asthma quality of life: a population-based study. Chest 2006;129: 285-291.
12. Magnan A, Meunier JP, Saugnac C, et al. Frequency and impact of allergic rhinitis in asthma patients in everyday general medical practice: a French observational cross-sectional study. Allergy 2008;63:292-298.
13. Valovirta E, Pawankar R. Survey on the impact of comorbid allergic rhinitis in patients with asthma. BMC Pulm Med 2006;6(suppl 1):S3.
14. Crystal-Peters J, Neslusan C, Crown WH, et al. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol 2002; 109:57-62.
15. Harding SM. Gastroesophageal reflux and asthma: insight into the association. J Allergy Clin Immunol 1999;104:251-259.
16. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol 2007;120:S94-S138.
17. Wilson NM. Wheezy bronchitis revisited. Arch Dis Child 1989;64:1194-1199.
18. Chiang WC, Goh A, Ho L, et al. Paradoxical vocal cord dysfunction: when a wheeze is not asthma. Singapore Med J 2008;49:e110-e112.
19. Sly PD, Cahill P, Willet K, et al. Accuracy of mini peak flow meters in indicating changes in lung function in children with asthma. BMJ 1994; 308:572-574.
20. Frey U, Stocks J, Coates A, et al. Specifications for equipment used for infant pulmonary function testing. ERS/ATS Task Force on Standards for Infant Respiratory Function Testing. European Respiratory Society/American Thoracic Society. Eur Respir J 2000;16:731-740.
21. Birnbaum S, Barreiro TJ. Methacholine challenge testing: identifying its diagnostic role, testing, coding, and reimbursement. Chest 2007;131: 1932-1935.
22. Thomas M, Price D. Impact of comorbidities on asthma. Expert Rev Clin Immunol 2008;4:731-742.
23. Spahn JD, Covar RA. Weighing the risks of treatment versus nontreatment in pediatric asthma. Pediatr Clin North Am 2003;50:677-695.
24. Skoner JD, Schaffner TJ, Schad CA, et al. Addressing steroid phobia: improving the risk-benefit ratio with new agents. Allergy Asthma Proc 2008;29:358-364.
25. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments [review]. Am J Respir Crit Care Med 1998;157:S1-S53.
26. Sin DD, Man J, Sharpe H, et al. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA 2004;292:367-376.
27. Suissa S, Ernst P. Inhaled corticosteroids: impact on asthma morbidity and mortality [review]. J Allergy Clin Immunol 2001;107:937-944.
28. Nelson HS, Weiss ST, Bleecker ER, et al; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26.
29. Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma [review]. Allergy 2006;61:518-526.
30. Kelly HW, Nelson HS. Potential adverse effects of the inhaled corticosteroids. J Allergy Clin Immunol 2003;112:469-478; quiz 479.
31. Derendorf H. Corticosteroid pharmacokinetic/pharmacodynamic parameters and their relationship to safety and efficacy. Allergy Asthma Proc 2005;26:327-335.
32. Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest 2004;126:213-219.
33. Canonica GW, Baena-Cagnani CE, Blaiss MS, et al; GAPP Survey Working Group. Unmet needs in asthma: Global Asthma Physician and Patient (GAPP) survey: global adult findings. Allergy 2007;62:668-674.
34. Juniper EF. The impact of patient compliance on effective asthma management [review]. Curr Opin Pulm Med 2003;9(suppl 1):S8-S10.
35. Bender BG, Rand C. Medication non-adherence and asthma treatment cost. Curr Opin Allergy Clin Immunol 2004;4:191-195.
36. Geller DE. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir Care 2005;50:1313-1321; discussion 1321-1322.
37. Feddah MR, Brown KF, Gipps EM, et al. In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates. J Pharm Pharm Sci 2000;3:318-324.
38. Sutherland ER, Martin RJ. Targeting the distal lung in asthma: do inhaled corticosteroids treat all areas of inflammation? Treat Respir Med 2005;4:223-229.
39. Dolovich MA. Influence of inspiratory flow rate, particle size, and airway caliber on aerosolized drug delivery to the lung. Respir Care 2000; 45:597-608.
40. Dietzel K, Engelstätter R, Keller A. Ciclesonide: An On-Site-Activated Steroid, in Hansel TT, Barnes PJ (eds): New Drugs for Asthma, Allergy and COPD Progress in Respiratory Research. Switzerland, Karger, 2001, vol 31, pp 91-93.
41. Cerasoli F Jr. Developing the ideal inhaled corticosteroid [review]. Chest 2006;130:54S-64S.
42. Rohatagi S, Luo Y, Shen L, et al. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am J Ther 2005;12:201-209.
43. Wagner EH, Austin BT, Davis C, et al. Improving chronic illness care: translating evidence into action. Health Aff (Millwood) 2001;20:64-78.
44. Kellerman R. The patient centered medical home - a new model of practice in the USA. Aust Fam Physician 2009;38:279.
45. Stewart M, Marshall JN, Østbye T, et al. Effectiveness of case-based on-line learning of evidence-based practice guidelines. Fam Med 2005; 37:131-138.
46. Wang YY. Patient-centered medicine: transforming the clinical method. Second edition. Int J Integr Care 2005;5:1-2.
47. Krigsman K, Nilsson JL, Ring L. Adherence to multiple drug therapies: refill adherence to concomitant use of diabetes and asthma/COPD medication. Pharmacoepidemiol Drug Saf 2007;16:1120-1128.
48. Gibson PG, Ram FS, Powell H. Asthma education. Respir Med 2003; 97:1036-1044.
49. Cowie RL, Revitt SG, Underwood MF, et al. The effect of a peak flow-based action plan in the prevention of exacerbations of asthma. Chest 1997;112:1534-1538.
50. Irwin RS, Richardson ND. Patient-focused care: using the right tools [review]. Chest 2006;130:73S-82S.
51. Broder MS, Chang EY, Ory C, et al. Adherence and persistence with omalizumab and fluticasone/salmeterol within a managed care population. Allergy Asthma Proc 2009;30:148-157.